Inefficient T-cell activation in the tumor microenvironment limits immunotherapy efficacy, which is addressed by engineering specific fused pyrimidine heterocyclic cores to selectively inhibit HPK1. These precise molecular architectures optimize binding affinity and metabolic stability to enhance anti-tumor immune responses.